Research Output Journal of Public Health and Medicine 5(3):71-78, 2025

ROJPHM

ISSN ONLINE: 1115-9715
ISSN PRINT: 1115-6147

https://rojournals.org/roj-public-health-and-medicine/

https://doi.org/10.59298/ROJPHM/2025/537178

Flavonoid-Induced Browning of White Adipose Tissue: A Strategy against Obesity-Associated Inflammation and Glucose Dysregulation

Nalongo Bina K.

Faculty of Medicine Kampala International University Uganda

ABSTRACT

Obesity is a major global health concern that significantly contributes to the development of metabolic syndromes such as insulin resistance, type 2 diabetes, and chronic low-grade inflammation. White adipose tissue (WAT), the primary site for energy storage, can undergo "browning" to become metabolically active beige adipocytes, characterized by enhanced mitochondrial activity and uncoupling protein 1 (UCP1) expression. Recent research has identified flavonoids which is naturally occurring polyphenolic compounds abundant in fruits, vegetables, and plant-derived foods as potent inducers of WAT browning. This review comprehensively discusses the molecular mechanisms by which flavonoids promote the browning of WAT, focusing on the activation of AMP-activated protein kinase (AMPK), peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), and the sympathetic nervous system. Additionally, we explore how flavonoid-induced browning alleviates obesity-related inflammation and improves glucose homeostasis. The therapeutic potential of various flavonoid subclasses such as catechins, anthocyanins, flavonols, and isoflavones is critically analyzed with supporting in vivo and in vitro evidence. We also highlight the translational challenges and future directions for clinical application. Flavonoid-based nutraceutical interventions represent a promising strategy to combat obesity and its associated metabolic disturbances through the induction of thermogenic adipocytes.

Keywords: Flavonoids, White Adipose Tissue, Browning, Obesity, Inflammation, Glucose Dysregulation, Thermogenesis, UCP1, AMPK, PGC-1α

INTRODUCTION

Obesity is a complex, multifactorial, and chronic metabolic condition characterized by an abnormal or excessive accumulation of body fat, primarily due to an imbalance between energy intake and expenditure[1–4]. This pathological state is not only a major public health concern but also a significant risk factor for a variety of metabolic disorders including type 2 diabetes mellitus, insulin resistance, cardiovascular diseases, non-alcoholic fatty liver disease (NAFLD), and certain forms of cancer[5–7]. At the cellular level, obesity is marked by excessive expansion and dysfunction of adipose tissue, particularly white adipose tissue (WAT), which plays a central role in energy storage. As WAT expands beyond its physiological capacity, it undergoes significant structural and functional changes that promote a pro-inflammatory environment, increase oxidative stress, and contribute to systemic metabolic dysregulation[5, 8, 9]. Conventional strategies to manage obesity primarily involve caloric restriction, dietary regulation, increased physical activity, and behavioural modification[10, 11]. While these lifestyle interventions are foundational in obesity prevention and treatment, their effectiveness is often limited by poor long-term adherence, metabolic adaptation, and individual variability. Pharmacological interventions are available, but they are frequently accompanied by side effects and limited efficacy, particularly in sustaining weight loss over time[11]. Consequently, there is a growing interest in identifying novel and sustainable therapeutic approaches that not only target adiposity but also ameliorate the associated metabolic complications. In recent years, the concept of promoting the "browning" of white adipose tissue has garnered significant attention as a promising strategy to combat obesity and its related disorders. Browning refers to the process by which white adipocytes—cells typically responsible for energy storage—are reprogrammed to acquire features resembling those of brown adipocytes[12]. Brown adipose tissue (BAT) is a specialized fat

depot characterized by a high mitochondrial content and the expression of uncoupling protein 1 (UCP1), which enables the dissipation of energy as heat through a process known as non-shivering thermogenesis. By enhancing thermogenic capacity and increasing energy expenditure, browning of WAT offers a metabolically advantageous approach for weight management and metabolic health improvement[13]. Emerging evidence suggests that certain bioactive compounds, particularly flavonoids, can serve as natural inducers of WAT browning. Flavonoids are a diverse group of polyphenolic compounds ubiquitously found in fruits, vegetables, tea, and other plant-based foods[14–16]. They have been widely studied for their antioxidant, anti-inflammatory, and anti-diabetic effects. More recently, their role in modulating adipose tissue function and promoting the browning of WAT has attracted scientific interest. Several flavonoids have been shown to upregulate thermogenic genes such as UCP1, PRDM16, and PGC-1α, enhance mitochondrial biogenesis, and improve insulin sensitivity in both in vitro and in vivo models[17, 18]. Given the global rise in obesity prevalence and its associated burden on health care systems, the exploration of flavonoids as modulators of adipose tissue phenotype represents a promising and innovative therapeutic avenue. This review aims to provide an in-depth overview of the current understanding of flavonoid-induced browning of white adipose tissue, elucidating the underlying molecular mechanisms and potential implications for the prevention and treatment of obesity and related metabolic disorders.

White Adipose Tissue Browning: An Overview

Adipose Tissue Plasticity: Adipose tissue, a specialized connective tissue, plays a central role in energy homeostasis and metabolic regulation. It primarily exists in two major forms—white adipose tissue (WAT) and brown adipose tissue (BAT)[19]. WAT serves as the body's primary site for long-term energy storage, housing lipid-filled white adipocytes that store excess calories in the form of triglycerides. In contrast, BAT is composed of mitochondria-rich brown adipocytes that expend energy through non-shivering thermogenesis, a process facilitated by uncoupling protein 1 (UCP1). UCP1 disrupts the proton gradient in the mitochondrial membrane, releasing energy as heat instead of producing ATP[20]. This makes BAT metabolically active and essential in temperature regulation, particularly in neonates and hibernating mammals. Remarkably, adipose tissue exhibits significant plasticity—the ability to transform in response to environmental and physiological stimuli[13, 21]. Under specific conditions such as chronic cold exposure, β-adrenergic stimulation, certain hormones (e.g., irisin), and pharmacological agents, WAT can undergo a process known as "browning." During browning, subsets of white adipocytes acquire characteristics akin to brown adipocytes, including multilocular lipid droplets, abundant mitochondria, and UCP1 expression. These newly formed thermogenic adipocytes are often referred to as "beige" or "brite" adipocytes[20]. This trans differentiation or recruitment of beige adipocytes represents an adaptive mechanism that contributes to increased energy expenditure and improved metabolic health. In animal models, browning of WAT has been associated with enhanced insulin sensitivity, resistance to diet-induced obesity, and improved lipid profiles[22]. Given these benefits, therapeutic strategies aimed at promoting adipose tissue browning are being explored for the treatment of obesity and metabolic diseases. However, the extent and persistence of browning in adult humans remain areas of active investigation. Understanding the molecular and cellular mechanisms governing adipose tissue plasticity is crucial for harnessing its potential in combating metabolic disorders.

Molecular Markers of Browning: The process of browning in white adipose tissue is characterized by a distinct molecular signature that resembles brown adipose tissue. Several key markers and regulatory pathways have been identified that not only define beige adipocyte identity but also orchestrate their formation and function[23]. One of the hallmark markers of brown and beige adipocytes is uncoupling protein 1 (UCP1). UCP1 is located in the inner mitochondrial membrane and plays a critical role in thermogenesis by uncoupling oxidative phosphorylation, allowing the dissipation of the proton gradient as heat rather than ATP synthesis.[24] Another essential factor is PR domain containing 16 (PRDM16), a transcriptional co-regulator that acts as a master regulator of brown fat determination. PRDM16 drives the expression of thermogenic genes and suppresses white adipocyte-specific genes, facilitating the browning process[25]. Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) is another key transcriptional coactivator involved in mitochondrial biogenesis and oxidative metabolism. It works in concert with PRDM16 and other transcription factors to promote the thermogenic gene program. Additionally, type II iodothyronine deiodinase (DIO2), which converts the prohormone thyroxine (T4) into the active thyroid hormone triiodothyronine (T3), enhances thermogenic capacity by upregulating UCP1 and mitochondrial activity[26].

The activation of the sympathetic nervous system (SNS) is a major physiological trigger for browning, primarily through β-adrenergic signaling that increases intracellular cyclic AMP (cAMP) and activates downstream effectors. Key intracellular pathways that regulate browning include the AMP-activated protein kinase (AMPK) pathway, which promotes energy expenditure; peroxisome proliferator-activated receptor gamma (PPARγ), which regulates adipocyte differentiation; and sirtuin 1 (SIRT1), which influences mitochondrial function and gene expression[26, 27]. Collectively, these molecular markers and pathways provide insights into the

mechanisms underlying adipose tissue browning and are potential targets for therapeutic interventions against obesity and metabolic disorders.

Flavonoids: Structure, Classification, and Bioavailability

Classification; Flavonoids are a diverse group of naturally occurring polyphenolic compounds widely distributed in the plant kingdom and are known for their significant roles in plant pigmentation, UV filtration, symbiotic nitrogen fixation, and defense against pathogens. They are broadly classified into six major subclasses based on their chemical structure and oxidation state of the central pyran ring[28–30]. These include flavanols, flavones, flavanones, flavanols, anthocyanins, and isoflavones. Flavanols, such as quercetin and kaempferol, are characterized by a hydroxyl group at the 3-position of the C-ring and are found in a wide variety of fruits and vegetables.[29, 31]. Flavones, including apigenin and luteolin, differ by lacking the 3-hydroxyl group and are commonly present in celery and parsley. Flavanones, like naringenin and hesperidin, are typical in citrus fruits and are known for their spasmolytic and antioxidant properties[32, 33]. Flavanols, which include catechins and epicatechins, are abundant in tea and cocoa and are especially noted for their cardiovascular benefits. Anthocyanins, responsible for the red, blue, and purple colors in berries and grapes, include cyanidin and delphinidin and are known for their antioxidant potential[34]. Lastly, isoflavones, such as genistein and daidzein, are primarily found in soy products and exhibit estrogenic activity, contributing to their role in hormone-related health conditions. Each subclass displays unique structural attributes and biological functions, which influence their health-promoting effects and applications in disease prevention.

Bioavailability: Despite the extensive health benefits associated with flavonoids, their therapeutic potential is often limited by poor bioavailability. Bioavailability refers to the proportion of a compound that enters the circulation when introduced into the body and is thus available for physiological activity or therapeutic effect[35, 36]. Several factors contribute to the low bioavailability of flavonoids, including limited intestinal absorption, rapid metabolism in the liver and small intestine, and extensive interaction with gut microbiota. These processes often result in the transformation of flavonoids into less active or inactive metabolites, reducing their overall efficacy in vivo[37]. Moreover, the chemical form in which flavonoids are ingested—typically as glycosides—further influences their absorption, as these forms must first undergo enzymatic hydrolysis. To address these limitations, various strategies have been developed to enhance the bioavailability and efficacy of flavonoids. One approach involves the use of nanoparticle delivery systems, which encapsulate flavonoids to protect them from degradation and improve their intestinal uptake[38, 39]. Another strategy includes glycosylation, a chemical modification that can increase solubility and stability, thereby facilitating better absorption. Additionally, co-administration with other bioactive compounds or dietary fats may aid in the transport and absorption of flavonoids across the intestinal barrier. These technological and biochemical innovations aim to maximize the health benefits of flavonoids, ensuring that their promising antioxidant, anti-inflammatory, and anticancer properties can be effectively harnessed in clinical and nutritional applications.

Mechanisms of Flavonoid-Induced Browning

AMPK-PGC-1α-UCP1 Axis: The AMP-activated protein kinase (AMPK)-peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α)-uncoupling protein 1 (UCP1) signaling pathway is a critical molecular cascade involved in energy homeostasis, mitochondrial biogenesis, and adaptive thermogenesis[40, 41]. Flavonoids such as quercetin and resveratrol have been shown to activate AMPK, a cellular energy sensor that responds to changes in the AMP/ATP ratio. Upon activation, AMPK promotes the expression of PGC-1α, a master regulator of mitochondrial biogenesis. PGC-1α, in turn, upregulates UCP1, a thermogenic protein primarily expressed in brown and beige adipocytes. UCP1 uncouples oxidative phosphorylation from ATP production, leading to heat generation instead of energy storage[41–43]. This cascade facilitates the browning of white adipose tissue, enhancing energy expenditure and contributing to anti-obesity effects. By promoting mitochondrial function and increasing thermogenic capacity, this axis plays a pivotal role in counteracting metabolic disorders. The flavonoid-mediated activation of this axis thus holds significant therapeutic promise for the management of obesity and related metabolic syndromes. Importantly, such natural compounds may serve as safer alternatives or adjuncts to synthetic pharmacological agents targeting similar pathways, especially for long-term interventions aimed at improving metabolic health and energy metabolism.

β-Adrenergic Receptor Stimulation: Flavonoids are bioactive polyphenolic compounds that may influence energy metabolism by modulating the sympathetic nervous system (SNS). One significant mechanism involves the stimulation of β-adrenergic receptors, particularly the β3-adrenergic receptor subtype, which plays a vital role in the browning of white adipose tissue[44]. These receptors are activated by catecholamines such as norepinephrine, which are released during sympathetic nervous system activation.[44] Flavonoids, including catechins, naringenin, and luteolin, have been shown to enhance norepinephrine release or prolong its activity, thereby facilitating β3-adrenergic receptor stimulation. Activation of these receptors initiates a cascade of intracellular events that lead to increased cyclic AMP (cAMP) levels and protein kinase A (PKA) activation, ultimately inducing the expression of thermogenic genes such as UCP1[45, 46]. This process results in enhanced energy expenditure and promotes the browning of white adipocytes into beige fat, which is

characterized by a higher mitochondrial content and thermogenic capability. Thus, flavonoid-induced β-adrenergic stimulation represents a promising non-pharmacological approach to combat obesity and metabolic dysregulation. This mechanism underscores the potential of dietary flavonoids as functional compounds capable of activating key metabolic pathways associated with fat burning and energy dissipation[47].

Inhibition of Adipogenesis: Adipogenesis is the process by which preadipocytes differentiate into mature adipocytes, characterized by increased lipid accumulation and expression of adipogenic transcription factors. Key regulators of this process include CCAAT/enhancer-binding protein alpha (C/EBPα) and peroxisome proliferator-activated receptor gamma (PPARγ), both of which drive the expression of genes involved in lipid uptake, storage, and adipocyte maturation[48, 49]. Flavonoids, such as genistein, apigenin, and kaempferol, have been shown to inhibit adipogenesis by downregulating the expression and activity of these transcription factors. By interfering with the early and late stages of adipocyte differentiation, flavonoids reduce lipid droplet formation and promote a shift toward a thermogenic phenotype[50, 51]. Additionally, some flavonoids may enhance the expression of anti-adipogenic and thermogenic genes, including PRDM16 and UCP1, thereby promoting the browning of white adipose tissue[52, 53]. The suppression of adipogenesis not only curtails fat accumulation but also contributes to improved insulin sensitivity and metabolic balance. Thus, the anti-adipogenic properties of flavonoids provide a compelling basis for their inclusion in therapeutic strategies against obesity and its associated comorbidities. Their natural origin and multi-targeted action further highlight their potential as safe and effective modulators of adipose tissue plasticity and energy homeostasis.

Flavonoids and Inflammation in Obesity

Obesity-induced inflammation is primarily driven by the infiltration of macrophages into adipose tissue and the subsequent elevation in the secretion of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1)[54, 55]. This chronic low-grade inflammation contributes significantly to metabolic dysregulation, insulin resistance, and obesity-related comorbidities. A growing body of evidence highlights the potential of flavonoids—naturally occurring polyphenolic compounds found in fruits, vegetables, and other plant-based foods—as effective agents in mitigating obesity-induced inflammation. Flavonoids exert their anti-inflammatory effects through several key mechanisms. Firstly, they inhibit the activation of nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways, which are critical mediators in the inflammatory response[56, 57]. Secondly, flavonoids promote the polarization of macrophages from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype, thereby reducing inflammatory signaling and tissue damage. Additionally, flavonoids help decrease adipocyte hypertrophy—an enlargement of fat cells that is closely linked to inflammation and metabolic dysfunction. Among various flavonoids, epigallocatechin gallate (EGCG), found in green tea, and genistein, a soy isoflavone, have demonstrated pronounced anti-inflammatory effects in both in vitro and in vivo models of obesity[58, 59]. These compounds not only reduce inflammatory cytokine levels but also contribute to enhanced browning of white adipose tissue—a process characterized by increased mitochondrial activity and energy expenditure, which may further counteract obesity. Collectively, the anti-inflammatory actions of flavonoids, particularly EGCG and genistein, underscore their potential as therapeutic agents in managing obesity-related inflammation and its metabolic consequences.

Flavonoids and Glucose Homeostasis

Flavonoid-induced browning of white adipose tissue has been linked to significant improvements in insulin sensitivity and glucose metabolism. This effect is primarily attributed to enhanced expression of glucose transporter type 4 (GLUT4), which facilitates increased glucose uptake into cells, particularly in muscle and adipose tissues[60]. Additionally, flavonoids such as anthocyanins and flavanols enhance the activity of insulin receptor substrate-1 (IRS-1), a key signaling molecule in the insulin pathway that promotes efficient glucose utilization. These compounds also contribute to reduced hepatic gluconeogenesis, thereby lowering the production of glucose by the liver, which helps in maintaining normal blood glucose levels. Evidence from both animal and human studies supports the role of anthocyanins and flavanols in improving glucose uptake and reducing fasting glucose concentrations[60]. Through these mechanisms, flavonoids not only support better glycemic control but also offer a promising natural approach to managing insulin resistance and preventing the progression of type 2 diabetes. Their ability to stimulate the browning of white fat further enhances energy expenditure, contributing to improved metabolic profiles. Overall, flavonoid consumption may serve as an effective dietary strategy to enhance glucose homeostasis and mitigate the risks associated with metabolic disorders.

Translational Challenges and Future Perspectives

Limitations: One of the key limitations in the study of flavonoids in lipid metabolism is the variability in individual metabolism and microbiota composition. These factors can significantly affect the bioavailability and effectiveness of flavonoids, leading to inconsistent results across different individuals. The interaction between dietary flavonoids and the gut microbiota also varies from person to person, making it challenging to draw generalized conclusions. Furthermore, there is a lack of standardized dosing protocols for flavonoids, which

hinders the ability to establish effective therapeutic recommendations. Compounding this issue, long-term safety data regarding the consumption of flavonoid-enriched foods or supplements are limited. This gap in knowledge raises concerns regarding potential adverse effects when consumed over extended periods, underscoring the need for rigorous clinical trials to assess their safety and efficacy over time.

Future Directions: Future research on flavonoids should focus on the development of flavonoid-enriched functional foods designed to optimize lipid metabolism. This could involve fortifying common dietary products with bioactive flavonoids to create convenient and accessible interventions. Additionally, combining flavonoids with other known browning agents, such as polyunsaturated fatty acids or thermogenic compounds, may enhance their fat-burning potential, providing a synergistic approach to weight management. The use of advanced omics technologies, such as genomics, metabolomics, and microbiomics, could revolutionize our understanding of personalized responses to flavonoid consumption. By profiling individual variations in genetic makeup, metabolism, and microbiota, researchers can tailor flavonoid-based therapies to specific individuals, ensuring more effective and precise interventions for obesity and metabolic disorders.

CONCLUSION

Flavonoids represent a promising class of bioactive compounds that can induce the browning of white adipose tissue, offering a dual benefit of combating obesity-associated inflammation and glucose dysregulation. While preclinical studies provide compelling evidence, further clinical validation and formulation strategies are essential to harness their full therapeutic potential.

REFERENCES

1. Achari, A.E., Jain, S.K.: Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction. Int J Mol Sci. 18, 1321 (2017). https://doi.org/10.3390/ijms18061321
2. Aloo, S.O., Barathikannan, K., Oh, D.-H.: Polyphenol-rich fermented hempseed ethanol extracts improve obesity, oxidative stress, and neural health in high-glucose diet-induced *Caenorhabditis elegans*. Food Chemistry: X. 21, 101233 (2024). https://doi.org/10.1016/j.fochx.2024.101233
3. Annett, S., Moore, G., Robson, T.: Obesity and Cancer Metastasis: Molecular and Translational Perspectives. Cancers. 12, 3798 (2020). https://doi.org/10.3390/cancers12123798
4. Uti, D.E., Atangwho, I.J., Omang, W.A., Alum, E.U., Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obesity Medicine. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
5. Anguita-Ruiz, A., Bustos-Aibar, M., Plaza-Díaz, J., Mendez-Gutierrez, A., Alcalá-Fdez, J., Aguilera, C.M., Ruiz-Ojeda, F.J.: Omics Approaches in Adipose Tissue and Skeletal Muscle Addressing the Role of Extracellular Matrix in Obesity and Metabolic Dysfunction. International Journal of Molecular Sciences. 22, 2756 (2021). https://doi.org/10.3390/ijms22052756
6. Alum, E.U.: Optimizing patient education for sustainable self-management in type 2 diabetes. Discov Public Health. 22, 44 (2025). https://doi.org/10.1186/s12982-025-00445-5
7. Alum, E., P.C., U., Obeagu, E., Extension, K.P.: Beyond Pregnancy: Understanding the Long-Term Implications of Gestational Diabetes Mellitus. INOSR Scientific Research. 11, 63–71 (2024). https://doi.org/10.59298/INOSRSR/2024/1.1.16371
8. Bartelt, A., Widenmaier, S.B., Schlein, C., Johann, K., Goncalves, R.L.S., Eguchi, K., Fischer, A.W., Parlakgül, G., Snyder, N.A., Nguyen, T.B., Bruns, O.T., Franke, D., Bawendi, M.G., Lynes, M.D., Leiria, L.O., Tseng, Y.-H., Inouye, K.E., Arruda, A.P., Hotamisligil, G.S.: Brown adipose tissue thermogenic adaptation requires Nrf1-mediated proteasomal activity. Nat Med. 24, 292–303 (2018). https://doi.org/10.1038/nm.4481
9. Cho, Y.K., Lee, S., Lee, J., Doh, J., Park, J.-H., Jung, Y.-S., Lee, Y.-H.: Lipid remodeling of adipose tissue in metabolic health and disease. Exp Mol Med. 55, 1955–1973 (2023). https://doi.org/10.1038/s12276-023-01071-4
10. Umoru, G.U., Atangwho, I.J., David-Oku, E., Uti, D.E., Agwupuye, E.I., Obeten, U.N., Maitra, S., Subramaniyan, V., Wong, L.S., Aljarba, N.H., Kumarasamy, V.: Tetracarpidium conophorum nuts (African walnuts) up-regulated adiponectin and PPAR-γ expressions with reciprocal suppression of TNF-α gene in obesity. Journal of Cellular and Molecular Medicine. 28, e70086 (2024). https://doi.org/10.1111/jcmm.70086
11. Uti, D.E., Atangwho, I.J., Eyong, E.U., Umoru, G.U., Egbung, G.E., Rotimi, S.O., Nna, V.U.: African walnuts (Tetracarpidium conophorum) modulate hepatic lipid accumulation in obesity via reciprocal actions on HMG-CoA reductase and paraoxonase. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders). 20, 365–379 (2020)
12. Cheong, L.Y., Xu, A.: Intercellular and inter-organ crosstalk in browning of white adipose tissue: molecular mechanism and therapeutic complications. Journal of Molecular Cell Biology. 13, 466 (2021). https://doi.org/10.1093/jmcb/mjab038

13. Cheng, L., Wang ,Jingkang, Dai ,Hongyu, Duan ,Yuhui, An ,Yongcheng, Shi ,Lu, Lv ,Yinglan, Li ,Huimin, Wang ,Chen, Ma ,Quantao, Li ,Yaqi, Li ,Pengfei, Du ,Haifeng, and Zhao, B.: Brown and beige adipose tissue: a novel therapeutic strategy for obesity and type 2 diabetes mellitus. Adipocyte. 10, 48–65 (2021). https://doi.org/10.1080/21623945.2020.1870060
14. Ahn-Jarvis, J.H., Parihar, A., Doseff, A.I.: Dietary Flavonoids for Immunoregulation and Cancer: Food Design for Targeting Disease. Antioxidants. 8, 202 (2019). https://doi.org/10.3390/antiox8070202
15. Alum, E.U., Ugwu, O.P.C.: Beyond Nutrients: Exploring the Potential of Phytochemicals for Human Health. IAA JAS. 10, 1–7 (2023). https://doi.org/10.59298/IAAJAS/2023/4.1.3211
16. Alum, E.U, Nwuruku, A. O, Edwin, N.: Targeting oxidative stress in cancer management: The role of antioxidant phytochemicals. KJHS. 4, 1–10 (2024). https://doi.org/10.59568/KJHS-2024-4-2-01
17. Zhang, X., Li, X., Fang, H., Guo, F., Li, F., Chen, A., Huang, S.: Flavonoids as inducers of white adipose tissue browning and thermogenesis: signalling pathways and molecular triggers. Nutr Metab (Lond). 16, 47 (2019). https://doi.org/10.1186/s12986-019-0370-7
18. Chen, Q.-C., Wu, C., Cai, W.-F., Ni, Q., Lin, S.-X., Zheng, S.-W., Jiang, C.-P., Yi, Y.-K., Liu, Q., Shen, C.-Y.: Eriocitrin promotes browning of white adipose tissue and activates brown adipose tissue through regulating HSF1/PGC-1α pathways. Journal of Functional Foods. 127, 106758 (2025). https://doi.org/10.1016/j.jff.2025.106758
19. Choe, S.S., Huh, J.Y., Hwang, I.J., Kim, J.I., Kim, J.B.: Adipose Tissue Remodeling: Its Role in Energy Metabolism and Metabolic Disorders. Front Endocrinol (Lausanne). 7, 30 (2016). https://doi.org/10.3389/fendo.2016.00030
20. Richard, A.J., White, U., Elks, C.M., Stephens, J.M.: Adipose Tissue: Physiology to Metabolic Dysfunction. In: Endotext [Internet]. MDText.com, Inc. (2020)
21. Jayarathne, S., Koboziev, I., Park, O.-H., Oldewage-Theron, W., Shen, C.-L., Moustaid-Moussa, N.: Anti-Inflammatory and Anti-Obesity Properties of Food Bioactive Components: Effects on Adipose Tissue. Prev Nutr Food Sci. 22, 251–262 (2017). https://doi.org/10.3746/pnf.2017.22.4.251
22. Machado, S.A., Pasquarelli-do-Nascimento, G., Silva, D.S. da, Farias, G.R., Santos, I. de O., Baptista, L.B., Magalhães, K.G.: Browning of the white adipose tissue regulation: new insights into nutritional and metabolic relevance in health and diseases. Nutrition & Metabolism. 19, 61 (2022). https://doi.org/10.1186/s12986-022-00694-0
23. Ziqubu, K., Dludla, P.V., Mthembu, S.X.H., Nkambule, B.B., Mabhida, S.E., Jack, B.U., Nyambuya, T.M., Mazibuko-Mbeje, S.E.: An insight into brown/beige adipose tissue whitening, a metabolic complication of obesity with the multifactorial origin. Front Endocrinol (Lausanne). 14, 1114767 (2023). https://doi.org/10.3389/fendo.2023.1114767
24. Chan, M., Lim, Y.C., Yang, J., Namwanje, M., Liu, L., Qiang, L.: Identification of a natural beige adipose depot in mice. Journal of Biological Chemistry. 294, 6751–6761 (2019). https://doi.org/10.1074/jbc.RA118.006838
25. Mao, L., Lu, J., Hou, Y., Nie, T.: Directly targeting PRDM16 in thermogenic adipose tissue to treat obesity and its related metabolic diseases. Front Endocrinol (Lausanne). 15, 1458848 (2024). https://doi.org/10.3389/fendo.2024.1458848
26. Machado, S.A., Pasquarelli-do-Nascimento, G., da Silva, D.S., Farias, G.R., de Oliveira Santos, I., Baptista, L.B., Magalhães, K.G.: Browning of the white adipose tissue regulation: new insights into nutritional and metabolic relevance in health and diseases. Nutrition & Metabolism. 19, 61 (2022). https://doi.org/10.1186/s12986-022-00694-0
27. Uti, D.E., Atangwho, I.J., Alum, E.U., Egba, S.I., Ugwu, O.P.-C., Ikechukwu, G.C.: Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. Natural Product Communications. 20, 1934578X251323393 (2025). https://doi.org/10.1177/1934578X251323393
28. Alkhalidy, H., Wang, Y., Liu, D.: Dietary Flavonoids in the Prevention of T2D: An Overview. Nutrients. 10, 438 (2018). https://doi.org/10.3390/nu10040438
29. Mahmoud, A.M., Hernández Bautista, R.J., Sandhu, M.A., Hussein, O.E.: Beneficial Effects of Citrus Flavonoids on Cardiovascular and Metabolic Health. Oxid Med Cell Longev. 2019, 5484138 (2019). https://doi.org/10.1155/2019/5484138
30. Liga, S., Paul, C., Péter, F.: Flavonoids: Overview of Biosynthesis, Biological Activity, and Current Extraction Techniques. Plants. 12, 2732 (2023). https://doi.org/10.3390/plants12142732
31. Cercato, L.M., Oliveira, J.P., Souza, M.T.S., Andrade, N., Martel, F., Camargo, E.A.: Effect of flavonoids in preclinical models of experimental obesity. PharmaNutrition. 16, 100260 (2021). https://doi.org/10.1016/j.phanu.2021.100260
32. Alum, E.U.: Phytochemicals in malaria treatment: Mechanisms of action and clinical efficacy. KJHS. 4, 71–84 (2024). https://doi.org/10.59568/KJHS-2024-4-2-06

33. Nouri, Z., Fakhri, S., El-Senduny, F.F., Sanadgol, N., Abd-ElGhani, G.E., Farzaei, M.H., Chen, J.-T.: On the Neuroprotective Effects of Naringenin: Pharmacological Targets, Signaling Pathways, Molecular Mechanisms, and Clinical Perspective. Biomolecules. 9, 690 (2019). https://doi.org/10.3390/biom9110690
34. Khoo, H.E., Azlan, A., Tang, S.T., Lim, S.M.: Anthocyanidins and anthocyanins: colored pigments as food, pharmaceutical ingredients, and the potential health benefits. Food Nutr Res. 61, 1361779 (2017). https://doi.org/10.1080/16546628.2017.1361779
35. Aqil, F., Munagala, R., Jeyabalan, J., Vadhanam, M.V.: Bioavailability of phytochemicals and its enhancement by drug delivery systems. Cancer Lett. 334, 133–141 (2013). https://doi.org/10.1016/j.canlet.2013.02.032
36. Bhalani, D.V., Nutan, B., Kumar, A., Singh Chandel, A.K.: Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics. Biomedicines. 10, 2055 (2022). https://doi.org/10.3390/biomedicines10092055
37. Bešlo, D., Golubić, N., Rastija, V., Agić, D., Karnaš, M., Šubarić, D., Lučić, B.: Antioxidant Activity, Metabolism, and Bioavailability of Polyphenols in the Diet of Animals. Antioxidants (Basel). 12, 1141 (2023). https://doi.org/10.3390/antiox12061141
38. Ciupei, D., Colişar, A., Leopold, L., Stănilă, A., Diaconeasa, Z.M.: Polyphenols: From Classification to Therapeutic Potential and Bioavailability. Foods. 13, 4131 (2024). https://doi.org/10.3390/foods13244131
39. Poudwal, S., Misra, A., Shende, P.: Role of lipid nanocarriers for enhancing oral absorption and bioavailability of insulin and GLP-1 receptor agonists. Journal of Drug Targeting. 29, 834–847 (2021). https://doi.org/10.1080/1061186X.2021.1894434
40. Bort, A., Sánchez, B.G., Spínola, E., Mateos-Gómez, P.A., Rodríguez-Henche, N., Díaz-Laviada, I.: The red pepper's spicy ingredient capsaicin activates AMPK in HepG2 cells through CaMKKβ. PLoS One. 14, e0211420 (2019). https://doi.org/10.1371/journal.pone.0211420
41. Dong, J., Zhang, X., Zhang, L., Bian, H.-X., Xu, N., Bao, B., Liu, J.: Quercetin reduces obesity-associated ATM infiltration and inflammation in mice: a mechanism including AMPKα1/SIRT1. Journal of Lipid Research. 55, 363 (2014). https://doi.org/10.1194/jlr.M038786
42. Woonnoi, W., Suttithumsatid, W., Muneerungsee, N., Saetan, J., Tanasawet, S., Sukketsiri, W.: Sangyod rice extract inhibits adipocyte growth and differentiation via mTOR, Akt, and AMPK pathways. Journal of Functional Foods. 111, 105913 (2023). https://doi.org/10.1016/j.jff.2023.105913
43. Cui, Y., Chen, J., Zhang, Z., Shi, H., Sun, W., Yi, Q.: The role of AMPK in macrophage metabolism, function and polarisation. Journal of Translational Medicine. 21, 892 (2023). https://doi.org/10.1186/s12967-023-04772-6
44. Kang, H.W., Lee, S.G., Otieno, D., Ha, K.: Flavonoids, Potential Bioactive Compounds, and Non-Shivering Thermogenesis. Nutrients. 10, 1168 (2018). https://doi.org/10.3390/nu10091168
45. Baldi, A., Abramovič, H., Poklar Ulrih, N., Daglia, M.: Tea Catechins. In: Xiao, J., Sarker, S.D., and Asakawa, Y. (eds.) Handbook of Dietary Phytochemicals. pp. 1–46. Springer, Singapore (2020)
46. Basu, T., Selman, A., Reddy, A.P., Reddy, P.H.: Current Status of Obesity: Protective Role of Catechins. Antioxidants (Basel). 12, 474 (2023). https://doi.org/10.3390/antiox12020474
47. Schirinzi, V., Poli, C., Berteotti, C., Leone, A.: Browning of Adipocytes: A Potential Therapeutic Approach to Obesity. Nutrients. 15, 2229 (2023). https://doi.org/10.3390/nu15092229
48. Kazemi, N., Ramazani, E., Tayarani-Najaran, Z.: In vitro effects of phytochemicals on adipogenesis with a focus on molecular mechanisms: A systematic review. Iran J Basic Med Sci. 28, 409–425 (2025). https://doi.org/10.22038/ijbms.2025.78924.17090
49. Wilson, N., Steadman, R., Muller, I., Draman, M., Rees, D.A., Taylor, P., Dayan, C.M., Ludgate, M., Zhang, L.: Role of Hyaluronan in Human Adipogenesis: Evidence from in-Vitro and in-Vivo Studies. IJMS. 20, 2675 (2019). https://doi.org/10.3390/ijms20112675
50. Allemailem, K.S., Almatroudi, A., Alharbi, H.O.A., AlSuhaymi, N., Alsugoor, M.H., Aldakheel, F.M., Khan, A.A., Rahmani, A.H.: Apigenin: A Bioflavonoid with a Promising Role in Disease Prevention and Treatment. Biomedicines. 12, 1353 (2024). https://doi.org/10.3390/biomedicines12061353
51. Guedj, F., Siegel, A.E., Pennings, J.L.A., Alsebaa, F., Massingham, L.J., Tantravahi, U., Bianchi, D.W.: Apigenin as a Candidate Prenatal Treatment for Trisomy 21: Effects in Human Amniocytes and the Ts1Cje Mouse Model. The American Journal of Human Genetics. 107, 911–931 (2020). https://doi.org/10.1016/j.ajhg.2020.10.001
52. Salehi, B., Venditti, A., Sharifi-Rad, M., Kręgiel, D., Sharifi-Rad, J., Durazzo, A., Lucarini, M., Santini, A., Souto, E.B., Novellino, E., Antolak, H., Azzini, E., Setzer, W.N., Martins, N.: The Therapeutic Potential of Apigenin. Int J Mol Sci. 20, 1305 (2019). https://doi.org/10.3390/ijms20061305

53. Charrière, K., Schneider, V., Perrignon-Sommet, M., Lizard, G., Benani, A., Jacquin-Piques, A., Vejux, A.: Exploring the Role of Apigenin in Neuroinflammation: Insights and Implications. Int J Mol Sci. 25, 5041 (2024). https://doi.org/10.3390/ijms25095041
54. Javaid, H.M.A., Ko, E., Joo, E.J., Kwon, S.H., Park, J.-H., Shin, S., Cho, K.W., Huh, J.Y.: TNFα-induced NLRP3 inflammasome mediates adipocyte dysfunction and activates macrophages through adipocyte-derived lipocalin 2. Metabolism. 142, 155527 (2023). https://doi.org/10.1016/j.metabol.2023.155527
55. Liang, W., Qi, Y., Yi, H., Mao, C., Meng, Q., Wang, H., Zheng, C.: The Roles of Adipose Tissue Macrophages in Human Disease. Front Immunol. 13, 908749 (2022). https://doi.org/10.3389/fimmu.2022.908749
56. Strizova, Z., Benesova, I., Bartolini, R., Novysedlak, R., Cecrdlova, E., Foley, L.K., Striz, I.: M1/M2 macrophages and their overlaps – myth or reality? Clin Sci (Lond). 137, 1067–1093 (2023). https://doi.org/10.1042/CS20220531
57. Wculek, S.K., Dunphy, G., Heras-Murillo, I., Mastrangelo, A., Sancho, D.: Metabolism of tissue macrophages in homeostasis and pathology. Cell Mol Immunol. 19, 384–408 (2022). https://doi.org/10.1038/s41423-021-00791-9
58. Andreu Fernández, V., Almeida Toledano, L., Pizarro Lozano, N., Navarro Tapia, E., Gómez Roig, M.D., De la Torre Fornell, R., García Algar, Ó.: Bioavailability of Epigallocatechin Gallate Administered with Different Nutritional Strategies in Healthy Volunteers. Antioxidants (Basel). 9, 440 (2020). https://doi.org/10.3390/antiox9050440
59. Legeay, S., Rodier, M., Fillon, L., Faure, S., Clere, N.: Epigallocatechin Gallate: A Review of Its Beneficial Properties to Prevent Metabolic Syndrome. Nutrients. 7, 5443–5468 (2015). https://doi.org/10.3390/nu7075230
60. Huang, Y., Zhou, T., Zhang, Y., Huang, H., Ma, Y., Wu, C., Wang, Q., Lin, Q., Yang, X., Pang, K.: Antidiabetic activity of a Flavonoid-Rich extract from flowers of *Wisteria sinensis* in type 2 diabetic mice via activation of the IRS-1/PI3K/Akt/GLUT4 pathway. Journal of Functional Foods. 77, 104338 (2021). https://doi.org/10.1016/j.jff.2020.104338

CITE AS: Nalongo Bina K. (2025). Flavonoid-Induced Browning of White Adipose Tissue: A Strategy against Obesity-Associated Inflammation and Glucose Dysregulation. Research Output Journal of Public Health and Medicine 5(3):71-78. https://doi.org/10.59298/ROJPHM/2025/537178